News

Business Wire20d
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
This antigen is combined with GSK’s proprietary AS01 E adjuvant. The vaccine has been approved for the prevention of RSV-LRTD in individuals 60 years of age and older in 61 countries ...